Skip to Content

Eucrisa FDA Approval History

FDA Approved: Yes (First approved December 14, 2016)
Brand name: Eucrisa
Generic name: crisaborole
Dosage form: Topical Ointment
Company: Pfizer Inc.
Treatment for: Atopic Dermatitis

Eucrisa (crisaborole) is a phosphodiesterase 4 inhibitor indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.

Development Timeline for Eucrisa

DateArticle
Mar 24, 2020ApprovalFDA Approves Eucrisa (crisaborole) Ointment 2% in Children as Young as 3 Months of Age With Mild-to-Moderate Atopic Dermatitis
Dec 14, 2016ApprovalFDA Approves Eucrisa (crisaborole) for Eczema
Mar 22, 2016Anacor Pharmaceuticals Announces FDA Acceptance of NDA for Crisaborole Topical Ointment, 2% for the Treatment of Mild-to-Moderate Atopic Dermatitis
Jan  7, 2016Anacor Pharmaceuticals Submits NDA to the FDA for Crisaborole Topical Ointment, 2% for the Treatment of Mild-to-Moderate Atopic Dermatitis

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.